Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: Findings from the National Health and Wellness Survey

Timothy Bell, MHA; Kathy Annunziata, MA; John B. Leslie, MD, MBA

doi:10.5055/jom.2009.0014

Authors

Timothy Bell, MHA
Kathy Annunziata, MA
John B. Leslie, MD, MBA

DOI:

https://doi.org/10.5055/jom.2009.0014

Keywords:

constipation, opioid, quality-of-life, productivity, pain management

Abstract

Objective: To characterize the impact of opioidinduced constipation (OIC) on healthcare resource use, work productivity, and health-related quality of life (HRQOL) in patients receiving chronic opioid therapy.
Design: Data were collected via Internet questionnaires during the international National Health and Wellness Survey (NHWS) 2004 from individuals aged ≥18 years who reported taking opioids for ≥6 months. Healthcare resource utilization, Work Productivity, and Activity Impairment, and Short-Form 8 (SF-8) questionnaire responses were compared between those who did or did not report OIC.
Results: Data were available from 2,430 individuals receiving opioids, of whom 359 reported OIC. Participants with OIC reported significantly more physician visits (mean difference 3.84 visits; p < 0.05) and alternative care provider visits (mean difference 1.73 visits; p < 0.05) over the previous 6 months than those without OIC; however, no significant differences in emergency room visits or number of days of hospitalization were observed. Respondents with OIC also reported significantly greater time missed from work, impairment while working, overall work impairment, and activity impairment (p < 0.05 for all comparisons). HRQOL scores were significantly lower in the OIC group than those without OIC on both the physical and mental components of the SF-8 questionnaire (p < 0.05 for both comparisons).
Conclusions: The survey results reflect a negative impact of OIC on individuals’ HRQOL and on society in terms of healthcare resource use and work productivity beyond that imposed by patients’ pain conditions. These findings indicate a need for effective treatment for opioid-induced constipation in patients receiving chronic opioid therapy.

Author Biographies

Timothy Bell, MHA

GlaxoSmithKline, Research Triangle Park, North Carolina.

Kathy Annunziata, MA

Consumer Health Sciences, Princeton, New Jersey.

John B. Leslie, MD, MBA

Mayo Clinic College of Medicine, Scottsdale, Arizona.

References

Kalso E, Edwards JE, Moore RA, et al.: Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain. 2004; 112: 372-380.

Moore RA, McQuay HJ: Prevalence of opioid adverse events in chronic non-malignant pain: Systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005; 7: R1046-R1051.

Pappagallo M: Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001; 182: 11S-18S.

Furlan AD, Sandoval JA, Mailis-Gagnon A, et al.: Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. CMAJ. 2006; 174: 1589-1594.

Glare P, Walsh D, Sheehan D: The adverse effects of morphine: A prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care. 2006; 23: 229-235.

De Luca A, Coupar IM: Insights into opioid action in the intestinal tract. Pharmacol Ther. 1996; 69: 103-115.

Wood JD, Galligan JJ: Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004; 16 (Suppl 2): 17-28.

Kurz A, Sessler DI: Opioid-induced bowel dysfunction: Pathophysiology and potential new therapies. Drugs. 2003; 63: 649-671.

McNicol E, Horowicz-Mehler N, Fisk RA, et al.: Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. J Pain. 2003; 4: 231-256.

Schug SA, Zech D, Grond S, et al.: A long-term survey of morphine in cancer pain patients. J Pain Symptom Manage. 1992; 7: 259-266.

Greenwood-Van Meerveld B, Gardner CJ, Little PJ, et al.: Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil. 2004; 16 (Suppl 2): 46-53.

Dreverman JW, Van der Poel AJ: Loperamide oxide in acute diarrhoea: A double-blind, placebo-controlled trial. The Dutch Diarrhoea Trialists Group. Aliment Pharmacol Ther. 1995; 9: 441-446.

Efskind PS, Bernklev T, Vatn MH: A double-blind placebocontrolled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol. 1996; 31: 463-468.

Sun WM, Read NW, Verlinden M: Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol. 1997; 32: 34-38.

Cascinu S, Bichisao E, Amadori D, et al.: High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. Support Care Cancer. 2000; 8: 65-67.

Brown L, Lawrie I, D’Sa VB, et al.: Constipation: Patient perceptions compared to diagnostic tools. Palliat Med. 2006; 20: 717-718.

Rauck RL, Bookbinder SA, Bunker TR, et al.: Oral once-aday AVINZA® (morphine sulfate extended-release capsules) vs. twice daily OxyContin® (oxycodone hydrochloride controlledrelease) for the treatment of chronic moderate-to-severe low back pain; final (part I and part II) study results. J Pain. 2006; 7 (Suppl 1): Abstract 827.

Fallon MT, Hanks GW: Morphine, constipation and performance status in advanced cancer patients. Palliat Med. 1999; 13: 159-160.

National Health and Wellness Survey: Consumer health sciences. Available at www.nhwsurvey.com/method. Accessed October 2008.

Harris Interactive. Available at www.harrisinteractive.com. Accessed June 2009.

Reilly MC, Zbrozek AS, Dukes EM: The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993; 4: 353-365.

Ware JE Jr, Kosinski M, Dewey JE, et al.: A Manual for Users of the SF-8 Health Survey. Lincoln, RI: QualityMetric Inc., 2001.

Wahlqvist P, Carlsson J, Stalhammar NO, et al.: Validity of a Work Productivity and Activity Impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD)–Results from a cross-sectional study. Value Health. 2002; 5: 106-113.

Reilly MC, Bracco A, Ricci JF, et al.: The validity and accuracy of the Work Productivity and Activity Impairment questionnaire–Irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther. 2004;20:459-467.

Leslie J, Bell T, Annunziata K, et al.: Opioid-induced constipation compromises pain management and impacts patient quality of life. Anesthesiology. 2006; 105: Abstract 1490.

Annunziata K, Freedman D, Janning S, et al.: Constipation is a predominant side effect of opioid treatment for persistent pain. J Pain. 2006; 7 (Suppl 1): Abstract 6083.

Longstreth GF, Thompson WG, Chey WD, et al.: Functional bowel disorders. Gastroenterology. 2006; 130: 1480-1491.

Bell T, Milanova T, Grove G, et al.: Prevalence, severity and impact of opioid-induced GI side effects on the EU: Results of a patient survey. Eur J Pain. 2006; 10 (Suppl 1): Abstract 663.